ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2006) 11 P699

Effects of metformin therapy in lean subjects with pcos on insulin resistance indices

Yuksel Altuntas1, Okcan Basat1, Sema Ucak1, Selcuk Seber1, Nezake Eren2, Cigdem Y Ersoy1 & Kubra Arslan1

1Sisli Etfal Research and Training Hospital, Diabetes Endocrinology and Metabolism, Istanbul, Turkey; 2isli Etfal Research and Training Hospital, Biochemistry, Istanbul, Turkey.

Objective: Polycystic ovary syndrome (PCOS) is closely associated with insulin resistance (IR) and about 50–70% of women with PCOS have significantly increased IR. Our study was performed to determine the effects of metformin on IR indices with lean PCOS patients.

Methods: Our study was a single center, randomized prospective study, approved by the local ethical committee. 53 patients with BMI <25 kg/m2 who had chronic anovulation and hyperandrogenism without any other specific causes of adrenal or pituitary disease and also met the diagnostic criteria for PCOS of the NIH Consensus, were considered to be eligible for the study. Patients were treated with 850 mg metformin twice daily for 24 weeks.

Results: Various indices of insulin sensitivity were used. Fasting insulin, Raynaud index, HOMA-IR and FIRI decreased significantly after treatment with metformin (P<0.05 for all). Fasting Belfiore index, QUICKY index, ISI HOMA and FIRI−1 increased significantly at the end of 24 weeks of treatment period (P<0.05 for all).

Conclusion: In conclusion, even in lean patients with PCOS, metformin treatment provided a significant improvement in IR. Therefore metformin should be considered an integral part of therapy also in lean PCOS patients.

Article tools

My recent searches

No recent searches.